4
Apr
2024
A ProfoundBio Windfall, Amylyx Yanks Failed ALS Drug, & Verve’s Rough Patch
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2024
How CymaBay Survived a Safety Scare
In November 2019, Sujal Shah was the CEO of a public company with two promising late-stage clinical trials underway. The company was worth more than $900 million. A couple months later, he found himself cornered in a parking lot by an activist investor—one of a handful pressuring him to shut down and liquidate his company CymaBay Therapeutics. “I can smile... Read More